Kim Kelderman

Kim Kelderman

DirectoratBIO-TECHNE· In proxies 2021–2025

Pay in FY2025BIO-TECHNE stock -28.2% the same year

Kim Kelderman was paid $8.2M in FY2025 (Jun). BIO-TECHNE stock fell 28.2% that year.

Pay$100 in the stock at the end of FY22 → $68
Pay is from the Summary Compensation Table of each BIO-TECHNE proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. CONMEDPublic company · 1 yr
    • Director2025 – Present · 1 yrNo stock prices for these years
  2. BIO-TECHNEPublic company · 5 yr
    • President and CEO2021 – Present · 5 yrStock in role +12%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?